s-1-(combination) and Chromosome-Inversion

Adjuvant chemotherapy by S-1 following gastrectomy is considered standard treatment in Japan. Analysis of follow-up data have proved the efficacy of S-1 administration, and that hematological adverse events were relatively rare. Pyrimidine anti-metabolites, including S-1, have shown relatively lower risks for secondary hematological malignancies in comparison to alkylating agents and topoisomerase-II inhibitors. We here report a case of therapy-related leukemia after S-1 administration. A patient who had received S-1as the sole adjuvant chemotherapy was diagnosed with acute erythroid leukemia. To the best of our knowledge, our patient represents the first report of S-1 induced acute leukemia.

Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Chromosome Inversion; Drug Combinations; Humans; Leukemia, Erythroblastic, Acute; Male; Neoplasms, Second Primary; Oxonic Acid; Tegafur